abrdn plc Purchases 449,053 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

abrdn plc increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 713.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 511,986 shares of the company's stock after acquiring an additional 449,053 shares during the period. abrdn plc's holdings in Teva Pharmaceutical Industries were worth $5,345,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TEVA. Blue Trust Inc. grew its position in Teva Pharmaceutical Industries by 92.3% in the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock worth $46,000 after acquiring an additional 2,180 shares in the last quarter. Signaturefd LLC boosted its position in Teva Pharmaceutical Industries by 90.8% during the third quarter. Signaturefd LLC now owns 5,032 shares of the company's stock valued at $51,000 after buying an additional 2,394 shares during the period. Desjardins Global Asset Management Inc. boosted its position in Teva Pharmaceutical Industries by 15.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company's stock valued at $85,000 after buying an additional 1,070 shares during the period. Schechter Investment Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $117,000. Finally, DGS Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $119,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares of the company's stock, valued at $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Eric Drape sold 9,815 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the completion of the transaction, the vice president now directly owns 9,701 shares in the company, valued at $127,277.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now owns 382,590 shares of the company's stock, valued at $5,172,616.80. The disclosure for this sale can be found here. Insiders sold a total of 390,738 shares of company stock valued at $5,132,766 over the last three months. Corporate insiders own 0.55% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on TEVA shares. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and upped their price target for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the company from $12.00 to $19.00 in a research report on Monday, February 12th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price target for the company in a research report on Friday, March 8th. The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a "neutral" rating in a research note on Monday, February 5th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 1st. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.78.

Teva Pharmaceutical Industries Trading Up 4.2 %

TEVA stock traded up $0.56 during trading on Friday, reaching $13.81. The company had a trading volume of 10,278,701 shares, compared to its average volume of 8,331,025. Teva Pharmaceutical Industries Limited has a 52 week low of $7.09 and a 52 week high of $14.47. The company has a market cap of $15.48 billion, a P/E ratio of -29.38, a PEG ratio of 1.65 and a beta of 1.05. The business has a 50 day moving average of $13.51 and a 200 day moving average of $11.42. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The company had revenue of $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.